Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
18F-fluoropivalate
- Development stage
- Phase 2
- Lead developer
- Radiopharm Theranostics, Ltd
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
18F-fluoropivalate ([18F]FPIA) is a novel radiopharmaceutical imaging agent developed by Imperial College London and licensed to Radiopharm Theranostics (under the code RAD 101). It is a small-molecule tracer designed to image short-chain fatty acid (SCFA) uptake, which serves as a proxy for fatty acid oxidation (FAO) in tumor cells. The tracer targets fatty acid synthase (FASN) and is particularly effective for imaging cerebral metastases because it exhibits low background signal in normal brain tissue, unlike glucose-based tracers. By quantifying the magnitude of early-step fatty acid oxidation, [18F]FPIA PET/MRI aims to differentiate between treatment-naïve metastases and those that have undergone stereotactic radiosurgery, providing a metabolic signature of viable tumor cells under bioenergetic stress.
- Brand names
- RAD 101RAD101RAD-101
- Other names
- 18F-FPIAFluorine-18 fluoropivalateFluorine18 fluoropivalateFluorine 18 fluoropivalateFluoropivalate F-18
02
Targets
FASN (Fatty acid synthase)
Beyond the preview
Go deeper on 18F-fluoropivalate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 18F-fluoropivalate.